Author

Paul Altmann

Institution: Oxford University Hospitals NHS Trust

Observed institutions: Guy's Hospital, St Thomas' Hospital, Queen Mary University of London, Aston University, Queen Elizabeth Hospital Birmingham, Leicester General Hospital, The Royal Free Hospital, Churchill Hospital, Southmead Hospital, Royal London Hospital, Southampton General Hospital, Chase Farm Hospital, John Radcliffe Hospital, University of Oxford, Oxford University Hospitals NHS Trust, King's College Hospital

OpenAlex ID: A5111882525

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

2005 · Colin Baigent, Martin Landray, et al. · American Journal of Kidney Diseases · 212

The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD

2006 · Martin Landray, Colin Baigent, et al. · American Journal of Kidney Diseases · 108

Disturbance of Cerebral Function by Aluminium in Haemodialysis Patients Without Overt Aluminium Toxicity

1989 · Paul Altmann, Chris Hamon, et al. · The Lancet · 93

Serum Aluminum Levels and Erythrocyte Dihydropteridine Reductase Activity in Patients on Hemodialysis

1987 · Paul Altmann, Farah Al-Salihi, et al. · New England Journal of Medicine · 72

Aluminium Chelation Therapy in Dialysis Patients: Evidence for Inhibition of Haemoglobin Synthesis by Low Levels of Aluminium

1988 · Paul Altmann, Frank Marsh, et al. · The Lancet · 62

Effect of Pamidronate on Bone Loss After Kidney Transplantation: A Randomized Trial

2009 · Stephen B. Walsh, Paul Altmann, et al. · American Journal of Kidney Diseases · 56

Implementation of a clinical decision support system improves compliance with restrictive transfusion policies in hematology patients

2015 · Caroline E. Butler, Simon Noel, et al. · Transfusion · 53

Residual renal function in hemodialysis patients may protect against hyperaluminemia

1987 · Paul Altmann, Keith C. Butter, et al. · Kidney International · 32

Penile calciphylaxis: an unusual cause of penile necrosis

2012 · Isha Prematilleke, Olivia Espinosa, et al. · Histopathology · 10

2003 · Jane Henderson, Paul Altmann · Nephron Clinical Practice · 6

Aluminium Induced Disease in Subjects with and without Renal Failure—Does It Help Us Understand the Role of Aluminium in Alzheimer’s Disease?

2001 · Paul Altmann · Elsevier eBooks · 5

Gallium-transferrin binding in Alzheimer disease

1990 · J.M Candy, C.M Morris, et al. · The Lancet · 4

Gallium (aluminium) transferrin binding in Alzheimer's disease

1992 · Gillian Farrar, Paul Altmann, et al. · The Lancet · 2

Hazards of gallium for the treatment of Paget's disease of bone

1990 · Paul Altmann, John Cunningham, et al. · The Lancet · 2

Comparative plasma speciation of the aluminium model ‘gallium-67’ in Alzheimers disease, stroke dementia, downs syndrome, end-stage renal disease and controls

1990 · Gillian Farrar, John A. Blair, et al. · Neurobiology of Aging · 1

Pulmonary, cardiac and renal syndrome

2000 · Jonathan M. Gleadle, David Davies, et al. · Nephrology Dialysis Transplantation

Pterin Metabolism In Haemodialysis Patients

1989 · Paul Altmann, Nick Sawyer, et al. · Pteridines

Works count: 19

Citation count: 718

H-index: 9

I10-index: 9